Another monoclonal antibody (D7F16) against VEGFR1 [132] has been shown to inhibit ligand-dependent VEGFR1 homodimerization and activation in human glioblastoma and glioblastoma stem cells [133]. The gene discussed is FLT1; the disease is glioblastoma.